Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…
Mani & O’Quinn Reimbursement Strategy Experts (MORSE) Consulting Inc. is pleased to introduce MORSE LINKS, a new feature on our website. MORSE LINKS provides a comprehensive list of useful web links which can allow market access professionals to easily access frequently referenced web sites. Similar to other services offered by MORSE, LINKS has a user-friendly interface with information separated into broad categories to allow users to sort and search based…
Biosimilar Panel On Tuesday, June 13, 2017, the Canadian Association for Healthcare Reimbursement (CAHR) held the Market Access 201 conference in Toronto. The theme for this conference was “Parallel or Intersecting Paths, the Future of Public and Private Reimbursement in Canada” which consisted of five fascinating panels focusing on key topics of interest to the Canadian pharmaceutical stakeholders. Over the coming weeks, MORSE will be releasing summaries for each…
Topic 1: PMPRB Panel On Tuesday, June 13, 2017, the Canadian Association for Healthcare Reimbursement (CAHR) held its Market Access 201 conference in Toronto. The theme for this conference was Parallel or Intersecting Paths, the Future of Public and Private Reimbursement in Canada which consisted of five engaging panels focusing on key topics of interest to the Canadian pharmaceutical stakeholders. Over the coming weeks, MORSE will be releasing summaries…
Great-West Life introduces the SMART drug plan In June 2017, Great-West Life is introducing the SMART drug plan, aiming for Sustainable, Managed and Reasonable Treatment. Like Manulife’s DrugWatch, SMART will bring more rigourous review to selected new drugs and indications and likely delay product entry into its formularies. Great-West Life indicates its reviews will not only rely on the Canadian Agency for Drugs and Technology in Health (CADTH). As…